Rani Therapeutics Holdings Inc

NASDAQ:RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. The company is headquartered in San Jose, California and currently employs 114 full-time employees. The company went IPO on 2021-07-30. The Company’s technologies enable the development of orally administered biologics. The firm has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The firm manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.